Impact of coronavirus disease 2019 on cancer care: How the pandemic has changed cancer utilization and expenditures.

Jinah Sim, Jihye Shin, Hyun Jeong Lee, Yeonseung Lee, Young Ae Kim
Author Information
  1. Jinah Sim: School of AI Convergence, Hallym University, Chuncheon, Republic of Korea.
  2. Jihye Shin: Department of Research, Health Insurance Review & Assessment Service (HIRA), Wonju, Republic of Korea.
  3. Hyun Jeong Lee: Division of Cancer Control & Policy, National Cancer Center, Gyeonggi, Republic of Korea.
  4. Yeonseung Lee: Division of Cancer Control & Policy, National Cancer Center, Gyeonggi, Republic of Korea.
  5. Young Ae Kim: Division of Cancer Control & Policy, National Cancer Center, Gyeonggi, Republic of Korea. ORCID

Abstract

PURPOSE: Since identified in December 2019, the novel coronavirus disease 2019 (COVID-19) has had a global impact on medical resource use and costs for patients with cancer in South Korea. This study aimed to identify the medical use and costs among patients with cancer during the COVID-19 pandemic, to predict these patterns in South Korea in the future.
METHODS: We conducted a secondary claims data analysis using the National Health Insurance Service database for the calendar period of 2019-2020. Monthly relative percent changes in cancer incidence, medical use, and billing costs for medical care utilization by cancer type were calculated. Then, the medical use and costs after January 2020 were predicted using a time series model with data before the COVID-19 outbreak (2014-2019).
RESULTS: The incidence of cancer diagnoses has seen a notable decline since the outbreak of the COVID-19 in 2020 as compared to 2019. Despite the impact of COVID-19, there hasn't been a distinct decline in outpatient utilization when compared to inpatient utilization. While medical expenses for both inpatient and outpatient visits have slightly increased, the number of patients treated for cancer has decreased significantly compared to the previous year. In June 2020, overall outpatient costs experienced the highest increase (21.1%), while individual costs showed the most significant decrease (-4.9%) in June 2020. Finally, the number of hospitalisations and outpatient visits increased slightly from June-July in 2020, reducing the difference between the actual and predicted values. The decrease in the number of inpatient hospitalisations (-22~-6%) in 2020 was also high.
CONCLUSIONS: The overall use of medical services by patients with cancer decreased in 2020 compared with that in the pre-COVID-19 pandemic period. In the future, the government should consider how to recover from the COVID-19 pandemic, and establish permanent health policies for patients with cancer.

References

  1. Cancer Discov. 2020 Jun;10(6):783-791 [PMID: 32345594]
  2. JAMA. 2021 Nov 16;326(19):1909-1910 [PMID: 34714325]
  3. Ann Surg. 2023 Nov 1;278(5):e960-e965 [PMID: 32487802]
  4. Health Aff (Millwood). 2022 Jan;41(1):13-25 [PMID: 34910596]
  5. Lancet Oncol. 2021 Jul;22(7):970-976 [PMID: 34051879]
  6. J Med Internet Res. 2020 Aug 20;22(8):e21257 [PMID: 32750008]
  7. Gen Hosp Psychiatry. 2019 Jul - Aug;59:1-6 [PMID: 31034963]
  8. Sci Rep. 2020 Oct 28;10(1):18422 [PMID: 33116179]
  9. Sci Rep. 2022 Jul 5;12(1):11380 [PMID: 35790880]
  10. Eur J Cancer. 2020 Dec;141:92-104 [PMID: 33130550]
  11. J Lipid Atheroscler. 2022 May;11(2):103-110 [PMID: 35656154]
  12. Ecancermedicalscience. 2020 Sep 08;14:1098 [PMID: 33082848]
  13. J Natl Cancer Inst. 2021 Nov 2;113(11):1484-1494 [PMID: 34258611]
  14. Int J Infect Dis. 2021 Mar;104:742-745 [PMID: 33556610]
  15. Yonsei Med J. 2023 Jul;64(7):463-470 [PMID: 37365741]
  16. Lancet. 2020 Jun 20;395(10241):1907-1918 [PMID: 32473681]
  17. Sci Rep. 2021 Dec 28;11(1):24470 [PMID: 34963690]
  18. J Cancer Res Clin Oncol. 2023 Jul;149(8):5345-5367 [PMID: 36436091]
  19. Front Med (Lausanne). 2020 Jul 28;7:429 [PMID: 32850915]
  20. ESMO Open. 2020 May;5(Suppl 3): [PMID: 32423899]
  21. Lancet. 2022 Aug 20;400(10352):563-591 [PMID: 35988567]
  22. Int J Environ Res Public Health. 2023 Feb 09;20(4): [PMID: 36833742]
  23. Am J Infect Control. 2020 Sep;48(9):1080-1086 [PMID: 32522606]
  24. Int J Equity Health. 2020 Jun 26;19(1):104 [PMID: 32586388]
  25. Clin Exp Emerg Med. 2021 Jun;8(2):137-144 [PMID: 34237819]
  26. Postgrad Med J. 2020 Jul;96(1137):399-402 [PMID: 32366457]
  27. Lancet Oncol. 2020 Mar;21(3):335-337 [PMID: 32066541]
  28. MMWR Morb Mortal Wkly Rep. 2020 Sep 11;69(36):1250-1257 [PMID: 32915166]
  29. Clin Cancer Res. 2018 Jan 15;24(2):266-275 [PMID: 28765323]
  30. Front Biosci (Landmark Ed). 2021 May 30;26(6):149-170 [PMID: 34162043]
  31. Asian Pac J Cancer Prev. 2011;12(3):725-30 [PMID: 21627372]
  32. Int J Environ Res Public Health. 2020 Aug 26;17(17): [PMID: 32858870]
  33. JAMA. 2020 Jun 2;323(21):2127-2128 [PMID: 32364565]
  34. JCO Clin Cancer Inform. 2020 Nov;4:1059-1071 [PMID: 33253013]
  35. Ann Intern Med. 2021 Aug;174(8):1101-1109 [PMID: 34058109]
  36. JAMA. 2020 Oct 20;324(15):1495-1496 [PMID: 33044484]
  37. Cancer Res Treat. 2022 Apr;54(2):352-361 [PMID: 34353000]
  38. Lancet Reg Health West Pac. 2023 Sep 21;41:100904 [PMID: 37780633]
  39. BMC Med. 2020 Oct 9;18(1):321 [PMID: 33032601]
  40. BMC Health Serv Res. 2022 Dec 2;22(1):1466 [PMID: 36461119]
  41. Eur J Cancer. 2020 Sep;136:69-75 [PMID: 32652443]
  42. Epidemiol Health. 2022;44:e2022044 [PMID: 35538696]
  43. Epidemiol Health. 2022;44:e2022053 [PMID: 35760396]
  44. JCO Oncol Pract. 2021 Aug;17(8):e1215-e1224 [PMID: 33739850]
  45. JAMA Oncol. 2021 Mar 1;7(3):458-460 [PMID: 33443549]
  46. Nat Cancer. 2020 Jun;1(6):565-567 [PMID: 35121972]
  47. Cancer Cell. 2020 Jun 8;37(6):738-741 [PMID: 32454025]

MeSH Term

Humans
Health Expenditures
Pandemics
COVID-19
Costs and Cost Analysis
Hospitalization
Neoplasms
Retrospective Studies

Word Cloud

Created with Highcharts 10.0.0cancermedical2020COVID-19costsusepatients2019pandemicutilizationcomparedoutpatientinpatientnumbercoronavirusdiseaseimpactSouthKoreafuturedatausingperiodincidencepredictedoutbreakdeclinevisitsslightlyincreaseddecreasedJuneoveralldecreasehospitalisationsPURPOSE:SinceidentifiedDecembernovelglobalresourcestudyaimedidentifyamongpredictpatternsMETHODS:conductedsecondaryclaimsanalysisNationalHealthInsuranceServicedatabasecalendar2019-2020MonthlyrelativepercentchangesbillingcaretypecalculatedJanuarytimeseriesmodel2014-2019RESULTS:diagnosesseennotablesinceDespitedistinctexpensestreatedsignificantlypreviousyearexperiencedhighestincrease211%individualshowedsignificant-49%FinallyJune-Julyreducingdifferenceactualvalues-22~-6%alsohighCONCLUSIONS:servicespre-COVID-19governmentconsiderrecoverestablishpermanenthealthpoliciesImpactcare:changedexpenditures

Similar Articles

Cited By